← CATALYST PHARMACEUTICALS, INC. CPRX
Market Price
$31.49
Market Cap
$3.85B
P/E Ratio
18.74
Revenue (FY 2025)
↑19.8% YoY
$588.99M
3-Yr CAGR: 40.1%
Net Income
↑30.8% YoY
$214.33M
Net Margin: 36.4%
Free Cash Flow
↓-12.8% YoY
$208.61M
FCF Yield: 5.41%
EPS (Diluted)
↑28.2% YoY
$1.68
Basic: $1.75
Return on Equity
Efficiency
22.5%
ROA: 1,010.2%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (CPRX)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | — | — | — | $-18.1M | — | $-0.22 | — | $-18.0M | $-18.1M | — |
| FY 2017 | — | — | — | $-18.4M | -1.9% | $-0.21 | +4.5% | $-13.7M | $-13.8M | +23.4% |
| FY 2018 | $0.5M | — | $0.4M | $-34.0M | -84.7% | $-0.33 | -57.1% | $-25.7M | $-25.8M | -86.4% |
| FY 2019 | $102.3M | +20,361.3% | $87.5M | $31.9M | +193.7% | $0.30 | +190.9% | $34.6M | $34.6M | +234.1% |
| FY 2020 | $118.7M | +16.1% | $101.7M | $75.0M | +135.2% | $0.71 | +136.7% | $45.0M | $45.0M | +30.2% |
| FY 2021 | $140.8M | +18.6% | $118.9M | $39.5M | -47.3% | $0.37 | -47.9% | $60.4M | $59.4M | +31.8% |
| FY 2022 | $214.2M | +52.1% | $179.8M | $83.1M | +110.4% | $0.75 | +102.7% | $116.0M | $116.0M | +95.5% |
| FY 2023 | $398.2M | +85.9% | $346.2M | $71.4M | -14.0% | $0.63 | -16.0% | $143.6M | $143.4M | +23.6% |
| FY 2024 | $491.7M | +23.5% | $422.9M | $163.9M | +129.5% | $1.31 | +107.9% | $239.8M | $239.3M | +66.9% |
| FY 2025 | $589.0M | +19.8% | $501.7M | $214.3M | +30.8% | $1.68 | +28.2% | $208.7M | $208.6M | -12.8% |
Valuation
Market Price
$31.49
Market Cap
$3.85B
Enterprise Value
N/A
P/E Ratio
18.74
P/B Ratio
4.04
FCF Yield
5.41%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
85.19%
Operating Margin
43.77%
Net Margin
36.39%
Return on Equity (ROE)
22.46%
Return on Assets (ROA)
1,010.21%
Asset Turnover
27.76x
Revenue 3-Yr CAGR
40.10%
Financial Health & Liquidity
Current Ratio
0.16
Cash Ratio
5.22
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$709.17M
Total Debt
N/A
Book Value / Share
$7.80
Cash Flow Efficiency
Operating Cash Flow
$208.67M
Capital Expenditures (CapEx)
$58.00K
Free Cash Flow
$208.61M
OCF / Revenue
35.43%
FCF / Revenue
35.42%
FCF 3-Yr CAGR
21.60%
Per Share Metrics
EPS (Diluted)
$1.68
EPS (Basic)
$1.75
Dividends / Share
N/A
Book Value / Share
$7.80
EPS YoY Growth
28.24%
Balance Sheet (FY 2025)
Total Assets
$21.22M
Total Liabilities
$135.95M
Stockholders' Equity
$954.27M
Current Assets
$21.22M
Current Liabilities
$135.95M